Among the 6 candidates obtained for 2 or more hub target genes, Fostamatinib is particularly important, targeting 7 hub target genes (LRRK2, PAK1, PRKACA, CSK, PIK3CG, CHEK1, PDE5A), which are targets of CD4+ T cells in Fingolimod for MS and targets of pDCs and PBMCs in IFN-β for MS. This evidence concerns the gene LRRK2 and myeloid sarcoma.